Nonlesional atopic dermatitis skin shares similar T‐cell clones with lesional tissues
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background: Atopic dermatitis (AD) is characterized by robust immune activation. Various T‐cell subsets, including Th2/Th22 cells, are increased in lesional and nonlesional skin. However, there is conflicting literature on the diversity of the T‐cell receptor (TCR) repertoire in lesional AD, and its relation to nonlesional skin remains unclear. Methods: We performed high‐throughput deep sequencing of the β‐TCR repertoire in 29 lesional and 19 nonlesional AD biopsies, compared to six healthy control and six cutaneous T‐cell lymphoma (CTCL) samples from previously published cohorts. Results: While greater T‐cell infiltrates were observed in lesional vs nonlesional AD, TCR repertoire diversity was similar in lesional and nonlesional tissues, and absolute numbers of unique T‐cell clones correlated with respective T‐cell counts. Most (87%) top expanded lesional T‐cell clones were shared with nonlesional tissues, and they were largely maintained after 16 weeks of successful treatment with topical triamcinolone. Nevertheless, both lesional and nonlesional AD showed a highly polyclonal TCR pattern, without evidence of oligoclonal expansion, or a preferred usage of certain V‐β genes in AD skin. Size of the overall T‐cell infiltrate, but not the level of clonality, correlated with mRNA levels of key inflammatory mediators (e.g., IL‐13, CCL 17, IL 23p19, CXCL 10). Conclusion: While AD harbors a highly polyclonal T‐cell receptor repertoire, and despite the lack of information on TCR antigen specificity, the sharing of top abundant clones between lesional and nonlesional skin, and their persistence after months of therapy, points to the continuous presence of potentially pathogenic skin resident memory T cells well beyond clinically inflamed lesions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weidinger, S., & Novak, N. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00149-x · Cited by 1,908
New insights into atopic dermatitis
Leung, D. Y. M., Boguniewicz, M., Howell, M. D., Nomura, I., & Hamid, Q. A. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21060 · Cited by 1,435
Comprehensive assessment of T-cell receptor β-chain diversity in αβ T cells
Robins, H. S., Campregher, P. V., Srivastava, S. K., Wacher, A., Turtle, C. J., Kahsai, O., Riddell, S. R., Warren, E. H., & Carlson, C. S. (2009) · Blood · doi:10.1182/blood-2009-04-217604 · Cited by 1,122
Gittler, J. K., Shemer, A., Suárez-Fariñas, M., Fuentes-Duculan, J., Gulewicz, K. J., Wang, C. Q. F., Mitsui, H., Cardinale, I., de Guzman Strong, C., Krueger, J. G., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.012 · Cited by 981 · cited 1×
“lesions, comparisons with acute lesions might also elicit different results.(5) The fact that the expansion of certain, limited Vb genes is lacking”
BackgroundSelf-citationNoda, S., Suárez-Fariñas, M., Ungar, B., Kim, S. J., de Guzman Strong, C., Xu, H., Peng, X., Estrada, Y. D., Nakajima, S., Honda, T., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.08.015 · Cited by 657
Self-citationNew insights into the epidemiology of childhood atopic dermatitis
Flohr, C., & Mann, J. (2014) · Allergy · doi:10.1111/all.12270 · Cited by 499 · cited 1×
“Atopic dermatitis (AD) is the most common chronic inflammatory skin disease, which affects about 15%-25% of children and 3%-7% of adults.(1,2) Established therapeutics include topical and systemic immunosuppressive agents, but AD usually recurs after cessation of therapy, and disease flares are common.”
BackgroundEarly-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin
Esaki, H., Brunner, P. M., Renert-Yuval, Y., Czarnowicki, T., Huynh, T., Tran, G., Lyon, S., Rodriguez, G., Immaneni, S., Johnson, D. B., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.07.013 · Cited by 428
Self-citationImpaired sphingomyelinase activity and epidermal differentiation in atopic dermatitis
Jensen, J.-M., Fölster-Holst, R., Baranowsky, A., Schunck, M., Winoto-Morbach, S., Neumann, C., Schütze, S., & Proksch, E. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.22621.x · Cited by 309
Does “autoreactivity” play a role in atopic dermatitis?
Tang, T. S., Bieber, T., & Williams, H. C. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.02.002 · Cited by 146 · cited 2×
“thioredoxin, or Hom s1 to Hom s4 epitopes, and they can correlate with disease activity.(45) Importantly, the development of IgE antibodies to a wide range of exogenous and endogenous agents requires antigen specific T cells for inducing IgE class switching, cells that”
Background
Cited by
Langan, S. M., Irvine, A. D., & Weidinger, S. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31286-1 · Cited by 1,852
Weidinger, S., Beck, L. A., Bieber, T., Kabashima, K., & Irvine, A. D. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0001-z · Cited by 1,549
Guttman-Yassky, E., Bissonnette, R., Ungar, B., Suárez-Fariñas, M., Ardeleanu, M., Esaki, H., Suprun, M., Estrada, Y., Xu, H., Peng, X., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.08.022 · Cited by 697
Self-citationAtopic dermatitis endotypes and implications for targeted therapeutics
Czarnowicki, T., He, H., Krueger, J. G., & Guttman-Yassky, E. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.10.032 · Cited by 631
Self-citationBiomarkers in atopic dermatitis—a review on behalf of the International Eczema Council
Renert-Yuval, Y., Thyssen, J. P., Bissonnette, R., Bieber, T., Kabashima, K., Hijnen, D., & Guttman-Yassky, E. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.01.013 · Cited by 350
“This is emphasized by the relatively normal clinical appearance of AD nonlesional skin, while tissue assessments unearth significant immune and barrier dysregulations, resembling lesional skin.(42,166) As we move toward more targeted therapies, AD biomarkers are important to appreciate patientspecific molecular dysreg…”
BackgroundSelf-citationUpdate on the Pathogenesis and Therapy of Atopic Dermatitis
Li, H., Zhang, Z., Zhang, H., Guo, Y., & Yao, Z. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08880-3 · Cited by 277
“Studies found that 5-year long-term management of mild-to-moderate AD in infants with TCSs or pimecrolimus 1% cream was safe without any effect on the immune system [77].”
BackgroundInfluentialCytokine-Mediated Crosstalk Between Keratinocytes and T Cells in Atopic Dermatitis
Humeau, M., Boniface, K., & Bodet, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.801579 · Cited by 75
“Importantly, persistence of identical T-cell clones in lesional and non-lesional AD skin suggests the involvement of resident memory T (TRM) cells, which are involved not only in disease progression and flares, but also during relapse of the disease (34), as previously shown in other chronic inflammatory dermatoses, s…”
Iwamoto, K., Nümm, T. J., Koch, S., Herrmann, N., Leib, N., & Bieber, T. (2018) · Allergy · doi:10.1111/all.13460 · Cited by 61
Clayton, K., Vallejo, A., Sirvent, S., Davies, J., Porter, G., Reading, I. C., Lim, F., Ardern‐Jones, M. R., & Polak, M. E. (2021) · British Journal of Dermatology · doi:10.1111/bjd.19431 · Cited by 28
Metadata
- Authors
- Brunner, P. M., Emerson, R. O., Tipton, C., Garcet, S., Khattri, S., Coats, I., Krueger, J. G., & Guttman‐Yassky, E.
- Venue
- Allergy
- Publisher
- Wiley
- Published
- 2017-06-28
- Volume
- 72
- Issue
- 12
- Pages
- 2017-2025
- ISSN
- 0105-4538 (ISSN-L)
- 1398-9995
- OpenAlex
- W2623798553
- Cited by
- 88
- References
- 9
- FWCI
- 7.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.